Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
In patients with acute myeloid leukemia (AML), treatment stratification is largely based on pretreatment factors, including cytogenetic and molecular aberrations and measurable/minimal residual disease (MRD) during treatment. Sequential MRD monitoring allows assessment of response to chemotherapy and early detection of relapse, potentially identifying patients in need of preemptive or more intensive therapy.